News | September 01, 2022
Merck India inaugurates R&D Excellence Centre in Bangalore
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
3D CMOS chip for connecting electroactive tissues and organoids to software
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Subscribe To Our Newsletter & Stay Updated
